Skip to main content
SpringerLink
Log in

On the Potential of Preemptive Genotyping Towards Preventing Medication-Related Adverse Events: Results from the South Korean National Health Insurance Database

  • Commentary
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 15 September 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther. 2012;92(2):235–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Kim GJ, Lee SY, Park JH, Ryu BY, Kim JH. Role of preemptive genotyping in preventing serious adverse drug events in South Korean Patients. Drug Saf. 2016. PubMed PMID: 27638658. doi:10.1007/s40264-016-0454-5.

  3. Shuldiner AR, Relling MV, Peterson JF, Hicks K, Freimuth RR, Sadee W, et al. The Pharmacogenomics research network translational pharmacogenetics program: overcoming challenges of real-world implementation. Clin Pharmacol Ther. 2013;94(2):207–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Manolio TA, Abramowicz M, Al-Mulla F, Anderson W, Balling R, Berger AC, et al. Global implementation of genomic medicine: We are not alone. Sci Transl Med. 2015;7(290):290ps13–290ps13.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012;92(1):87–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Schildcrout JS, Shi Y, Danciu I, Bowton E, Field JR, Pulley JM, et al. A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program. J Clin Epidemiol. 2016;72:107–15.

    Article  PubMed  Google Scholar 

  7. Van Driest SL, Shi Y, Bowton EA, Schildcrout JS, Peterson JF, Pulley J, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014;95(4):423–31.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA

    Jonathan S. Schildcrout

  2. Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, TN, USA

    Jonathan S. Schildcrout

  3. Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, USA

    Joshua C. Denny & Dan M. Roden

  4. Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA

    Joshua C. Denny & Dan M. Roden

  5. Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA

    Dan M. Roden

Authors
  1. Jonathan S. Schildcrout
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joshua C. Denny
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dan M. Roden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan S. Schildcrout.

Ethics declarations

Funding

This commentary was supported by the National Institute of General Medical Sciences (RC2GM092318, P50GM115305), the National Heart, Lung, and Blood Institute (R01HL094786, U01HL122904), the National Human Genome Research Institute (U01HG008672), the Centers for Disease Control and Prevention (U47CI000824), and the National Center for Advancing Translational Sciences (UL1TR000445).

Conflict of interest

Jonathan S. Schildcrout, Joshua C. Denny, and Dan M. Roden have no conflicts of interests directly relevant to the content of this commentary.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schildcrout, J.S., Denny, J.C. & Roden, D.M. On the Potential of Preemptive Genotyping Towards Preventing Medication-Related Adverse Events: Results from the South Korean National Health Insurance Database. Drug Saf 40, 1–2 (2017). https://doi.org/10.1007/s40264-016-0476-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-016-0476-z

Keywords

Search

Navigation